CN118401525A - 吡唑并[3,4-d]嘧啶化合物的固体形式 - Google Patents

吡唑并[3,4-d]嘧啶化合物的固体形式 Download PDF

Info

Publication number
CN118401525A
CN118401525A CN202280083751.7A CN202280083751A CN118401525A CN 118401525 A CN118401525 A CN 118401525A CN 202280083751 A CN202280083751 A CN 202280083751A CN 118401525 A CN118401525 A CN 118401525A
Authority
CN
China
Prior art keywords
solid form
certain embodiments
ray powder
powder diffraction
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280083751.7A
Other languages
English (en)
Chinese (zh)
Inventor
卡罗琳·伊薇特·普鲁克斯-拉弗朗斯
艾瑞卡·沃科瓦
小约翰·C·阿梅迪欧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER Ltd
Original Assignee
PFIZER Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER Ltd filed Critical PFIZER Ltd
Publication of CN118401525A publication Critical patent/CN118401525A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280083751.7A 2021-12-16 2022-12-16 吡唑并[3,4-d]嘧啶化合物的固体形式 Pending CN118401525A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163290136P 2021-12-16 2021-12-16
US63/290,136 2021-12-16
PCT/US2022/081795 WO2023114995A1 (en) 2021-12-16 2022-12-16 Solid forms of pyrazolo[3,4-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
CN118401525A true CN118401525A (zh) 2024-07-26

Family

ID=85172741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280083751.7A Pending CN118401525A (zh) 2021-12-16 2022-12-16 吡唑并[3,4-d]嘧啶化合物的固体形式

Country Status (11)

Country Link
US (2) US12012412B2 (https=)
EP (1) EP4448529A1 (https=)
JP (1) JP2024546844A (https=)
KR (1) KR20240119299A (https=)
CN (1) CN118401525A (https=)
AU (2) AU2022416644B2 (https=)
CA (1) CA3242577A1 (https=)
IL (1) IL313314A (https=)
MX (1) MX2024007517A (https=)
TW (1) TW202333676A (https=)
WO (1) WO2023114995A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12012412B2 (en) * 2021-12-16 2024-06-18 Pfizer Inc. Solid forms of pyrazolo[3,4-d]pyrimidine compounds
AU2024329573A1 (en) * 2023-08-22 2026-04-02 Cardurion Pharmaceuticals, Inc. Pyrazolo[3,4-d]pyrimidinone compounds for the treatment of chronic heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
RS52166B (sr) * 2007-05-11 2012-08-31 Pfizer Inc. Amino-heterociklična jedinjenja
CN109893653A (zh) * 2017-12-11 2019-06-18 王慧敏 Pde9抑制剂的新用途
US12012412B2 (en) 2021-12-16 2024-06-18 Pfizer Inc. Solid forms of pyrazolo[3,4-d]pyrimidine compounds

Also Published As

Publication number Publication date
MX2024007517A (es) 2024-08-19
AU2022416644A1 (en) 2024-07-04
NZ812114A (en) 2025-08-29
AU2025275149A1 (en) 2026-01-08
CA3242577A1 (en) 2023-06-22
KR20240119299A (ko) 2024-08-06
EP4448529A1 (en) 2024-10-23
TW202333676A (zh) 2023-09-01
IL313314A (en) 2024-08-01
JP2024546844A (ja) 2024-12-26
US12012412B2 (en) 2024-06-18
US20230192707A1 (en) 2023-06-22
WO2023114995A1 (en) 2023-06-22
AU2022416644B2 (en) 2025-09-11
US20240300961A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
TWI877197B (zh) Ｃｆｔｒ調節劑之結晶形式
JP2021523918A (ja) Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態
US20240300961A1 (en) Solid forms of pyrazolo[3,4-d]pyrimidine compounds
AU2009235440B2 (en) Anhydrous crystal form of orvepitant maleate
US12209073B2 (en) Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor
US20240083914A1 (en) Crystalline Polymorphs of a Muscarinic Acetylcholine Receptor Agonist
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
AU2019217821B2 (en) Co-crystal forms of a novobiocin analog and proline
EP2751094B1 (en) Novel crystal form
CN114072406A (zh) Flna-结合化合物及其盐酸盐的固体多晶型物
HK40112450A (zh) 吡唑并[3，4-d]嘧啶化合物的固体形式
JP2025503642A (ja) （ｓ）－５－ベンジル－ｎ－（５－メチル－４－オキソ－２，３，４，５－テトラヒドロピリド［３，２－ｂ］［１，４］オキサゼピン－３－イル）－４ｈ－１，２，４－トリアゾール－３－カルボキサミドの結晶性形態
US11136332B2 (en) Morphic forms of marizomib and uses thereof
EA052651B1 (ru) ТВЕРДЫЕ ФОРМЫ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫХ СОЕДИНЕНИЙ
US20220251091A1 (en) Amorphous umbralisib monotosylate
TW201908320A (zh) 一種ｂｔｋ激酶抑制劑的結晶形式及製備方法
US20240368165A1 (en) Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
CN119403807A (zh) 5H－吡咯并［2,3－d］嘧啶－6（7H）－酮及其盐体的结晶
JP2023524622A (ja) ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１Ｈ－ピラゾール－４－イル）－３Ｈ－イミダゾ［４，５－ｂ］ピリジンの塩及び多形体
HK40121018A (zh) 5h-吡咯并[2，3-d]嘧啶-6(7h)-酮及其盐体的结晶
HK40110051A (zh) 解旋酶-引发酶抑制剂的固体结晶形式及其制备方法
NZ792812A (en) Crystalline polymorphs of a muscarinic acetylcholine receptor agonist
HK1198534B (en) Novel crystal form

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40112450

Country of ref document: HK